Silexion Therapeutics ( ($SLXN) ) has provided an update. On May 22, 2025, Silexion Therapeutics Corp, a Cayman Islands exempted company, received ...

Silexion’s new groundbreaking study explores the potential impact of its next generation RNAI therapeutic candidate beyond pancreatic cancer aiming to address critical unmet needs in additional ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech company developing RNA interference (RNAi) ...

WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE 6,779,205 111,726** * Represents an amount less than $1 ** All share and per share ...

GRAND CAYMAN, Cayman Islands, May 13, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech company developing RNA ...

This article was originally published on Quiver News, read the full story. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of ...

Significant advancements in preclinical pipeline for SIL204, with groundbreaking data demonstrating efficacy against both primary tumors and metastases in orthotopic models; strengthened financial ...

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only ...

Research and development (including $0 and $17 from related parties for the three months period ended March 31, 2025 and 2024, respectively) $590 $961 General and administrative (including $21 and ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a ...